

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/262772 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C12N 15/13 (2006.01) *A61P 35/00* (2006.01)
C12P 21/08 (2006.01) *A61P 37/06* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/098929

(22) International Filing Date:

15 June 2022 (15.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/099998

15 June 2021 (15.06.2021) CN

(71) Applicant: **BEIJING SINOTAU BIO-PHARMA-
CEUTICALS TECHNOLOGY CO., LTD.** [CN/CN];
1st-2nd Floor, Building 1, No. 5, Tongji Middle Road, Bei-
jing Economic and Technological Development Area, Dax-
ing District, Beijing 100176 (CN).

(72) Inventors: **ZHONG, Xiaoyan**; 6 Middle Longyu Road,
Changping District, Beijing 100193 (CN). **LI, Zhe**; 32
Shayang Road, Changping District, Beijing 102206 (CN).
ZHU, Jie; Creativity Garden, Zhongguancun Life Science
Park, Changping District, Beijing 102206 (CN).

(74) Agent: **CHENG & PENG INTELLECTUAL PROPER-
TY LAW OFFICE**; 704, Block B, Xinyu Commercial
Building, 90 Guangqumen Inner Street, Dongcheng Dis-
trict, Beijing 100062 (CN).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-HER3 ANTIBODY, ANTIBODY DRUG CONJUGATE CONTAINING THE SAME, AND USE THEREOF

(57) Abstract: Provided is an anti-HER3 antibody, or an antibody drug conjugate (ADC) containing the anti-HER3 antibody. Also provided is the use of the antibody or ADC in the treatment of HER3-expression cancers.

WO 2022/262772 A1